Deltex Medical Group plc “Two new hospital accounts”

Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring (“ODM”), has told DirectorsTalk that it has added two new hospital accounts to its platform programme in the USA.

 

The first new hospital is a prestigious academic medical centre in the Company’s Mid-Atlantic sales territory. The hospital evaluated ODM in the third quarter of 2015 and becomes the fourth platform account in the territory since it was established in the final quarter of 2014.

 

The second new account is the first Veteran’s Affairs (‘VA’) hospital to decide to adopt ODM at sufficient scale to qualify as a platform programme account. Its decision to implement ODM follows a successful clinical evaluation in the second quarter of 2015 and the hospital becomes the fourth platform programme account in the Company’s West Coast sales territory. The VA provides the largest integrated health system in the USA and is entirely taxpayer funded: it operates over 150 medical centres across the USA including hospitals in most major cities. The Company hopes to make further progress into VA medical centres although this is likely to be in the medium to longer term.

 

Both new accounts have indicated that they expect to start implementation this month at around 50 probes a month and to expand usage over time.

 

These are the second and third new platform programme accounts that Deltex has secured in 2016 bringing the total number of US platform accounts to 20. This further illustrates the success of the Company’s ongoing strategy to focus on the USA as its key market.

 

Notice of results

 

The Company will be reporting its final results for the year ended 31 December 2015 on Tuesday, 12 April 2016.

 

Ewan Phillips, Deltex Medical’s Chief Executive, commented: “We have seen the USA become our key territory for development as adoption rates continue to outperform our other areas of focus over the last year. Getting to 20 platform programme accounts is an important step towards delivering Deltex’s US expansion strategy. Establishing a first platform programme account in the VA system is in itself also a major development.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc in a strong financial position

    Nigel Keen, Chairman of Deltex Medical, commented: “The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure. “We made a number

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group New CEO Andy Mears

    Deltex Medical Group Plc (LON:DEMG) New CEO Andy Mears talks to DirectorsTalk about his new position. Andy talks about his background, how he thinks Deltex is positioned, his plans for the next 12 months and the

    Deltex Medical Group Plc

    Deltex Medical Group plc New Chief Executive

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect. Mr. Phillips recently approached Deltex’s

    Deltex Medical Group Plc

    Another Successful Learning Event Sponsored by Deltex

    May 28th saw Deltex Medical Group supporting Current Initiatives, Research and the Role of Haemodynamic Monitoring at London’s Montague Hotel. Held under the auspices of the EBPOM organisation (Evidence Based PeriOperative Medicine), the congress saw keynote presentations from

    Deltex Medical Group Plc

    CEO Q&A with Ewan Phillips at Deltex Medical Group plc (LON:DEMG)

    Deltex Medical Group’s Ewan Phillips discusses their full year results, what’s been happening operationally, their strategy for the next 12 months and what investors should look forward to in the near future in this exclusive interview with DirectorsTalk

    Deltex Medical Group Plc

    Deltex Medical Group PLC Investor Event

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announced that it will be hosting an investor event on 22 May 2018 following the publication of its full year results for

    Deltex Medical Group Plc

    Deltex Sponsoring Evidence-Based Clinical Event

    Deltex Medical will be supporting a forthcoming congress in London on May 28th. Current Initiatives, Research and the Role of Hemodynamic Monitoring is free to attend for clinicians and healthcare providers who are interested in the principles and

    Deltex Medical Group Plc

    Critical caring

    It takes a plethora of products and people to provide patients premium protection. Changing payment models, the digitization of healthcare and the need to deliver higher quality care at a lower cost are driving significant change